January 22, 2022 Saturday 10:17
People in Hungary also need to test a vaccine called BriLife, developed by the biotechnology company NRx Pharmaceuticals and the Israeli Biological Research Institute, which has a special feature that works with a genetically modified virus, one of the company’s from its communication.
Although a second-phase study of the vaccine is yet to begin, researchers are still confident that I will be like Pfizer or Moderna, writes Jewish News Syndicate Israeli news portal.
Although BriLife vaccine induces immunity after a injectable injection,
its working principle is very different from the coronavirus vaccines currently in use, as it contains a live virus that grows spike proteins on its surface.
To put it very simply, the Israeli vaccine was developed by scientists taking a non-human vesicular stomatitis virus (VSV), which is common in horses and cattle and whose genetic stock has been modified to grow SARS-CoV-2 coronavirus spike proteins on the surface. This artificial pathogen was then propagated in test tubes to be used as a vaccine.
Although the genetically modified VSV virus is not a coronavirus, it is still able to elicit an immune response against the pathogen responsible for the epidemic, as coronavirus spike proteins peak in carrots.
Genetically modified viruses are a new technology used in the use of vaccines. In 2019, the European Medicines Agency (EMA) authorized an vaccine against Ebola called Ervebo, which also had a modified vesicular stomatitis virus.
The first phase clinical trial of BriLife vaccine, involving about 240 people, was completed on 16 November last year. As a result, it can be said that
the immune response elicited by the vaccine produced at least as many, but often more, antibodies against the coronavirus in humans than with Pfizer or Moderna.
The second phase of the study, which will test the effectiveness and safety of the vaccine, will begin shortly. It is interesting that Hungary is the first European country where the manufacturer is waiting for volunteers to apply for testing. Incidentally, NRx Pharmaceuticals had already agreed with the competent domestic authorities on 9 December last year.